NCT01610596View on ClinicalTrials.gov

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
PsoriasisPlaque Psoriasis
Interventions
DRUG

Halobetasol Propionate Lotion 0.05%

Apply twice daily for 1-2 weeks, not to exceed 50 grams per week

DRUG

Placebo

Trial Locations (3)

55432

Minnesota Clinical Study Center, Fridley

78759

DermResearch, Inc., Austin

92123

Therapeutics Clinical Research, San Diego

All Listed Sponsors
lead

Therapeutics, Inc.

INDUSTRY

NCT01610596 - A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis | Biotech Hunter | Biotech Hunter